Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists.
K A Grant, G Colombo, J Grant, M A Rogawski
Neuropharmacology 1996 DOI: 10.1016/s0028-3908(96)00147-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | dizocilpine phencyclidine ketamine dexoxadrol memantine remacemide ARL 12495 phencylcyclopentylamine dextromethorphan ADCI levoxadrol |
| Dose | 0.17 mg/kg |
| Key points | Low-affinity uncompetitive NMDA antagonists have discriminative stimulus properties distinct from dissociative anesthetic-type uncompetitive NMDA antagonists, with complete substitution for dizocilpine occurring only at rate-reducing doses for the more potent low-affinity antagonists. |
Abstract
The dizocilpine-like discriminative stimulus effects of a variety of channel blocking (uncompetitive) N-methyl-D-aspartate (NMDA) receptor antagonists were examined in rats trained to discriminate dizocilpine (0.17 mg/kg, i.p) from saline in a two-lever operant procedure. The dissociative anesthetic-type NMDA antagonists dizocilpine (ED50 0.05 mg/kg), phencyclidine (ED50 3.4 mg/kg) and ketamine (ED50 14 mg/kg) showed complete substitution without producing significant decreases in response rates, whereas dexoxadrol (ED50 4.3 mg/kg) also produced complete substitution with a concomitant decrease (35%) in response rate. Similarly, the low-affinity antagonist memantine resulted in complete substitution (ED50 9.7 mg/kg) at doses that significantly reduced (68%) the response rate. All other low-affinity antagonists resulted in either partial or no substitution for the discriminative stimulus effects of dizocilpine at doses that significantly decreased average response rates. These include (ED50 values in parentheses) remacemide (29 mg/kg), the remacemide metabolite 1,2-diphenyl-2-propylamine (ARL 12495) (14 mg/kg), phencylcyclopentylamine (25 mg/kg), dextromethorphan (46 mg/kg), (+/-)-5-aminocarbonyl-10,11-dihydro -5H-dibenzo-[a,d]cyclohepten-5,10-imine (ADCI; no substitution) and levoxadrol (no substitution). We conclude that low-affinity uncompetitive NMDA antagonists have discriminative stimulus properties distinct from dissociative anesthetic-type uncompetitive NMDA antagonists. The lowest-affinity antagonists show virtually no substitution for dizocilpine, whereas the relatively more potent low-affinity antagonists (such as memantine) exhibit greater substitution, but complete substitution is obtained only at rate-reducing doses.
Citations in the library
Cited by 3
- The ketamine analogue methoxetamine generalizes to ketamine discriminative stimulus in rats. Behavioural Pharmacology April 1, 2016
- Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine. European Journal of Pharmacology June 29, 2001
- Abuse liability assessment of neuroprotectants. Annals of the New York Academy of Sciences 1999
Cites 9
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology November 1994
- MK-801 and related compounds in monkeys: discriminative stimulus effects and effects on a conditional discrimination. Journal of Pharmacology and Experimental Therapeutics May 1, 1991
- Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. The Journal of Physiology January 1991
- N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis. Journal of Pharmacology and Experimental Therapeutics June 1, 1990
and 4 more in the library